NAS10026,816−5.70%S&P7,430−3.37%GOLD$4,105+0.80%BTC$75,995−5.48%VIX25.68+54.61%latest tape · as of 16:02 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Viatris
VTRS · a US exchange · USD · Market cap $21.9B · 30,000 employees
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
FAIL · Does not pass the screen
19.22 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 16:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price19.22 USD at the 4 Nov 2026 close
Our value readUndervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.35, read 2026-11-01
Ethical does not pass the values gate
Price19.22 USD
Fair value25.00
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup19.22+0.0% to today ✓Accumulation gives way to Markup after a 16% rise in 7 weeks
2026-09-16Read Accumulation16.50+16.5% to today ✓Distribution gives way to Accumulation after a 7% slide in 4 weeks
2026-08-16Read Distribution17.65+8.9% to today Markup gives way to Distribution after a 7% rise in 6 weeks
2026-07-02Read Markup16.48+16.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Viatris holds its Markup at $19.22. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$19.22
Valuation
N/A trailing · 7.05 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.86
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
39.52%
Below 33%
Interest-bearing debt is 39.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.19%
Below 33%
Cash held in interest-bearing accounts and securities is 2.2% of assets, under the one-third limit.
Pass
Receivables
10.49%
Below 49%
Money owed to the company is 10.5% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Viatris's business is in a permissible area, but its interest-bearing debt is about 40% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when VTRS's ethical verdict changes
Today VTRS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 24% discount to our $25.00 fair value, weak competitive moat, 4.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 23.1% discount to the base estimate.
Where our models see it going: fair-value estimate $25.00, with a range of $23.16 to $37.84, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Generic Pills Mask Heavy Debt Burden
Picture a pharmacy shelf stacked with familiar pills that once eased costs for patients worldwide. Viatris trades at a forward multiple of just 6.5 times yet we pass. Weak moat, negative profit margins of minus 2 percent and return on equity of minus 2 percent show a business that is not compounding value despite 8 percent revenue growth.
The ethical screen flags the debt ratio as a clear fail. That single red line overrides the apparent margin of safety to fair value and keeps us away even when eight analysts lean buy with an $18 median target.
Low multiples on eroding returns often signal a trap rather than a bargain. Currency swings and integration risks add further pressure in a sector where scale alone rarely rescues weak balance sheets. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VTRS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$19.22+1.6%Entry 16
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$18.92-0.6%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$19.04+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$19.04+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$19.04+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$19.04+5.8%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$18.00+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$18.00-3.5%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$18.66+7.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18.
2026-10-16Accumulation$17.44-4.5%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 81%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $18.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
